Clinical Trial

Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis Clinical Trial 20193199

[LCID Study Number: 20193199]

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Adult Patients Receiving Standard-of-Care Antibiotics for the Treatment of Staphylococcus aureus Bloodstream Infections (Bacteremia), Including Right-Sided Infective Endocarditis

The purpose of this trial is to evaluate the efficacy and safety of exebacase in addition to standard of care antibiotics (SoCA) compared with SoCA alone for the treatment of patients with Staphylococcus aureus (S. aureus) bloodstream infections (BSI), including right-sided infective endocarditis (IE).

Disease/Condition: Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis

Department: Pulmonary and Critical Care Medicine

Location(s): Lahey Hospital & Medical Center (Burlington)

Primary Contact Email:

Clinical Trial Details

View NCT ID 04160468 on

Protocol #: 20193199

Principal Investigator(s): Timothy N. Liesching

Study Coordinator(s): Yuxiu Lei

Trial Phase: Sponsor Initiated Study Phase 3